Corvus reports Q1 2026 net loss of $13.7M; cash $236.7M; soquelitinib trials advance

Corvus Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.15 vs consensus -$0.15 ▼ miss (-3.0%)

Net loss $13.7M in Q1 2026 vs net income $15.2M in Q1 2025; cash $236.7M (incl. $189.4M from Jan 2026 financing).
Phase 2 atopic dermatitis trial initiated (~200 patients, 4 dose cohorts, 12-week treatment).
Phase 3 registrational PTCL trial enrolling 150 patients; primary endpoint progression-free survival.
Partner Angel Pharma enrolling Phase 1b/2 atopic dermatitis trial in China; initial results expected late 2026.
New immunologic/biomarker data from Phase 1 to be presented at SID meeting on May 14, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $13.7 million.

Period: first quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was $13.7 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026 was $13.7 million

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.